Abstract:Discoidin domain receptors (DDR) play crucial roles in cell proliferation and differentiation. When DDRs are overexpressed, it has been associated with various diseases such as cancers, fibrotic disorders, and inflammation. This study aimed to expand on previous research by using a structure-based drug design approach to develop a series of new indole-urea derivatives as potent inhibitors of DDR1. Through biochemical analyses, it was found that these compounds effectively inhibited DDR1/2, with compound 7s demonstrating the highest activity against A549 cells (IC 50 value of 1.84 μM) while maintaining selectivity for other kinases. In vivo studies showed that compound 7s exhibited stronger antitumor activity compared to dasatinib , without causing significant weight loss at a dose of 30 mg/kg. Further investigation revealed that compound 7s hindered the migration of A549 cells by targeting the ERK, Akt1, and EMT pathways. Additionally, cellular experiments demonstrated that compound 7s suppressed the activation of fibroblasts induced by TGF-β1. In vivo experiments confirmed that compound 7s, at a dose of 30 mg/kg, effectively inhibited DDR1 activation, resulting in a reduction of lung injury and fibrosis induced by bleomycin. Overall, these findings highlight the potential of these novel DDR1 inhibitors as promising therapeutic candidates for the treatment of DDR-related diseases.

Design And Optimization Of 3 '-(Imidazo[1,2-Alpha]Pyrazin-3-Yl)-[1,1 '-Biphenyl]-3-Carboxamides As Selective Ddr1 Inhibitors

Discovery and Optimization of 3-(2-(pyrazolo[1,5-a]pyrimidin-6-yl)-ethynyl)benzamides As Novel Selective and Orally Bioavailable Discoidin Domain Receptor 1 (ddr1) Inhibitors

Discovery Of 4-Amino-1h-Pyrazolo [3,4-D] Pyrimidin Derivatives As Novel Discoidin Domain Receptor 1 (Ddr1) Inhibitors

Discovery of Pyrazolo[3,4- d ]pyridazinone Derivatives as Selective DDR1 Inhibitors via Deep Learning Based Design, Synthesis, and Biological Evaluation

Identification of Imidazo[4,5-C]pyridin-2-one Derivatives As Novel Src Family Kinase Inhibitors Against Glioblastoma.

Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor

Structure-Based Design of Tetrahydroisoquinoline-7-Carboxamides as Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors.

Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1h-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives As A New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer

Design, synthesis and anti-tumor evaluation of 1,2,4-triazol-3-one derivatives and pyridazinone derivatives as novel CXCR2 antagonists.

Design, Synthesis, and Biological Evaluation of 3-(Imidazo[1,2-a]pyrazin-3-ylethynyl)-4-isopropyl-n-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)benzamide As a Dual Inhibitor of Discoidin Domain Receptors 1 and 2

Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors

Design, Synthesis, and Evaluation of ( R )-8-((Tetrahydrofuran-2-yl)methyl)pyrido[2,3- d ]pyrimidin-7-ones as Novel Selective ACK1 Inhibitors to Combat Acquired Resistance to the Third-Generation EGFR Inhibitor

Design and Biological Evaluation of Novel Triaryl Pyrazoline Derivatives with Dioxane Moiety for Selective BRAFV600E Inhibition.

Discovery of Novel Dual Extracellular Regulated Protein Kinases (ERK) and Phosphoinositide 3-Kinase (PI3K) Inhibitors As a Promising Strategy for Cancer Therapy

Design, Synthesis and Biological Activity of 3-Pyrazine-2-yl-oxazolidin-2-ones As Novel, Potent and Selective Inhibitors of Mutant Isocitrate Dehydrogenase 1.

Discovery and Optimization of 1-(4-chloro-3-(trifluoromethyl)- Phenyl)-3-(2-(amino)pyridin-3-yl)ureas As Novel KDR Kinase Inhibitors.

Design, Synthesis and Biological Evaluation of Novel 3H-Imidazole [4,5-B] Pyridine Derivatives As Selective Mtor Inhibitors.

Synthesis, Biological Evaluation and Molecular Docking Studies of Pyrazole Derivatives Coupling with a Thiourea Moiety As Novel CDKs Inhibitors.

Design, synthesis, and biological evaluation of novel discoidin domain receptor inhibitors for the treatment of lung adenocarcinoma and pulmonary fibrosis

Identification of 3, 4-disubstituted pyridine derivatives as novel CDK8 inhibitors

Design, Synthesis, and Biological Evaluation of 2,4-Diaminopyrimidine Derivatives as Potent CDK7 Inhibitors